Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - RPT193

Antagonist of the CCR4 chemokine receptor

Drug - Placebo

Matching placebo

Additional Information

Official Study Title

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

Clinical Trial ID

NCT04271514

ParticipAid ID

dBBx2d